Two more biotech birds queue up IPOs while the window is open
This article was originally published in Scrip
An initial public offering window is open and won't be closing soon, according to newly-public Regulus Therapeutics' president and CEO Kleanthis Xanthopoulos, and two more biotech birds have set price ranges for their IPOs in hopes of flying the private company coop.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.